Global PROteolysis Targeting Chimera (PROTAC) Market Growth 2020-2025
According to this study, over the next five years the PROteolysis Targeting Chimera (PROTAC) market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PROteolysis Targeting Chimera (PROTAC) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of PROteolysis Targeting Chimera (PROTAC) market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the PROteolysis Targeting Chimera (PROTAC), covering the supply chain analysis, impact assessment to the PROteolysis Targeting Chimera (PROTAC) market size growth rate in several scenarios, and the measures to be undertaken by PROteolysis Targeting Chimera (PROTAC) companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
ARV-110
ARV-471
KYM-001
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Oncology
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Arvinas
AstraZeneca
Kymera
Captor therapeutics
Vividion
C4 therapeutics
Merck
Cullgen
Genentech
Pfizer
Amgen
Bayer
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global PROteolysis Targeting Chimera (PROTAC) consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of PROteolysis Targeting Chimera (PROTAC) market by identifying its various subsegments.
Focuses on the key global PROteolysis Targeting Chimera (PROTAC) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the PROteolysis Targeting Chimera (PROTAC) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of PROteolysis Targeting Chimera (PROTAC) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PROteolysis Targeting Chimera (PROTAC) Consumption 2015-2025
2.1.2 PROteolysis Targeting Chimera (PROTAC) Consumption CAGR by Region
2.2 PROteolysis Targeting Chimera (PROTAC) Segment by Type
2.2.1 ARV-110
2.2.2 ARV-471
2.2.3 KYM-001
2.2.4 Others
2.3 PROteolysis Targeting Chimera (PROTAC) Consumption by Type
2.3.1 Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
2.3.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue and Market Share by Type (2015-2020)
2.3.3 Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Type (2015-2020)
2.4 PROteolysis Targeting Chimera (PROTAC) Segment by Application
2.4.1 Oncology
2.4.2 Others
2.5 PROteolysis Targeting Chimera (PROTAC) Consumption by Application
2.5.1 Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
2.5.2 Global PROteolysis Targeting Chimera (PROTAC) Value and Market Share by Type (2015-2020)
2.5.3 Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Type (2015-2020)
3 Global PROteolysis Targeting Chimera (PROTAC) by Company
3.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Company
3.1.1 Global PROteolysis Targeting Chimera (PROTAC) Sales by Company (2018-2020)
3.1.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Company (2018-2020)
3.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Company
3.2.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Company (2018-2020)
3.2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Company (2018-2020)
3.3 Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Company
3.4 Global PROteolysis Targeting Chimera (PROTAC) Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global PROteolysis Targeting Chimera (PROTAC) Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players PROteolysis Targeting Chimera (PROTAC) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 PROteolysis Targeting Chimera (PROTAC) by Regions
4.1 PROteolysis Targeting Chimera (PROTAC) by Regions
4.2 Americas PROteolysis Targeting Chimera (PROTAC) Consumption Growth
4.3 APAC PROteolysis Targeting Chimera (PROTAC) Consumption Growth
4.4 Europe PROteolysis Targeting Chimera (PROTAC) Consumption Growth
4.5 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Growth
5 Americas
5.1 Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Countries
5.1.1 Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020)
5.1.2 Americas PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020)
5.2 Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Type
5.3 Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Regions
6.1.1 APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Regions (2015-2020)
6.1.2 APAC PROteolysis Targeting Chimera (PROTAC) Value by Regions (2015-2020)
6.2 APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Type
6.3 APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe PROteolysis Targeting Chimera (PROTAC) by Countries
7.1.1 Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020)
7.1.2 Europe PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020)
7.2 Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Type
7.3 Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) by Countries
8.1.1 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020)
8.2 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Type
8.3 Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 PROteolysis Targeting Chimera (PROTAC) Distributors
10.3 PROteolysis Targeting Chimera (PROTAC) Customer
11 Global PROteolysis Targeting Chimera (PROTAC) Market Forecast
11.1 Global PROteolysis Targeting Chimera (PROTAC) Consumption Forecast (2021-2025)
11.2 Global PROteolysis Targeting Chimera (PROTAC) Forecast by Regions
11.2.1 Global PROteolysis Targeting Chimera (PROTAC) Forecast by Regions (2021-2025)
11.2.2 Global PROteolysis Targeting Chimera (PROTAC) Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global PROteolysis Targeting Chimera (PROTAC) Forecast by Type
11.8 Global PROteolysis Targeting Chimera (PROTAC) Forecast by Application
12 Key Players Analysis
12.1 Arvinas
12.1.1 Company Information
12.1.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Arvinas Latest Developments
12.2 AstraZeneca
12.2.1 Company Information
12.2.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.2.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 AstraZeneca Latest Developments
12.3 Kymera
12.3.1 Company Information
12.3.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.3.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Kymera Latest Developments
12.4 Captor therapeutics
12.4.1 Company Information
12.4.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Captor therapeutics Latest Developments
12.5 Vividion
12.5.1 Company Information
12.5.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Vividion Latest Developments
12.6 C4 therapeutics
12.6.1 Company Information
12.6.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.6.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 C4 therapeutics Latest Developments
12.7 Merck
12.7.1 Company Information
12.7.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.7.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Merck Latest Developments
12.8 Cullgen
12.8.1 Company Information
12.8.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.8.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Cullgen Latest Developments
12.9 Genentech
12.9.1 Company Information
12.9.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Genentech Latest Developments
12.10 Pfizer
12.10.1 Company Information
12.10.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.10.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Pfizer Latest Developments
12.11 Amgen
12.11.1 Company Information
12.11.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Amgen Latest Developments
12.12 Bayer
12.12.1 Company Information
12.12.2 PROteolysis Targeting Chimera (PROTAC) Product Offered
12.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Bayer Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. PROteolysis Targeting Chimera (PROTAC) Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of ARV-110
Table 5. Major Players of ARV-471
Table 6. Major Players of KYM-001
Table 7. Major Players of Others
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Table 10. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2015-2020) ($ million)
Table 11. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Table 15. Global PROteolysis Targeting Chimera (PROTAC) Value by Application (2015-2020)
Table 16. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Application (2015-2020)
Table 17. Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Application (2015-2020)
Table 18. Global PROteolysis Targeting Chimera (PROTAC) Sales by Company (2017-2019) (K Units)
Table 19. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Company (2017-2019)
Table 20. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Company (2017-2019) ($ Millions)
Table 21. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Company (2017-2019)
Table 22. Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Company (2017-2019)
Table 23. Global PROteolysis Targeting Chimera (PROTAC) Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players PROteolysis Targeting Chimera (PROTAC) Products Offered
Table 25. PROteolysis Targeting Chimera (PROTAC) Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global PROteolysis Targeting Chimera (PROTAC) Consumption by Regions 2015-2020 (K Units)
Table 27. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Regions 2015-2020
Table 28. Global PROteolysis Targeting Chimera (PROTAC) Value by Regions 2015-2020 ($ Millions)
Table 29. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Regions 2015-2020
Table 30. Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020) (K Units)
Table 31. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries (2015-2020)
Table 32. Americas PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020) ($ Millions)
Table 33. Americas PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries (2015-2020)
Table 34. Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Type (2015-2020) (K Units)
Table 35. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Table 36. Americas PROteolysis Targeting Chimera (PROTAC) Consumption by Application (2015-2020) (K Units)
Table 37. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Table 38. APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Regions (2015-2020) (K Units)
Table 39. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Regions (2015-2020)
Table 40. APAC PROteolysis Targeting Chimera (PROTAC) Value by Regions (2015-2020) ($ Millions)
Table 41. APAC PROteolysis Targeting Chimera (PROTAC) Value Market Share by Regions (2015-2020)
Table 42. APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Type (2015-2020) (K Units)
Table 43. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Table 44. APAC PROteolysis Targeting Chimera (PROTAC) Consumption by Application (2015-2020) (K Units)
Table 45. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Table 46. Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020) (K Units)
Table 47. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries (2015-2020)
Table 48. Europe PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020) ($ Millions)
Table 49. Europe PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries (2015-2020)
Table 50. Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Type (2015-2020) (K Units)
Table 51. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Table 52. Europe PROteolysis Targeting Chimera (PROTAC) Consumption by Application (2015-2020) (K Units)
Table 53. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Countries (2015-2020) (K Units)
Table 55. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Type (2015-2020) (K Units)
Table 59. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption by Application (2015-2020) (K Units)
Table 61. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Table 62. PROteolysis Targeting Chimera (PROTAC) Distributors List
Table 63. PROteolysis Targeting Chimera (PROTAC) Customer List
Table 64. Global PROteolysis Targeting Chimera (PROTAC) Consumption Forecast by Countries (2021-2025) (K Units)
Table 65. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Forecast by Regions
Table 66. Global PROteolysis Targeting Chimera (PROTAC) Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share Forecast by Regions
Table 68. Global PROteolysis Targeting Chimera (PROTAC) Consumption Forecast by Type (2021-2025) (K Units)
Table 69. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global PROteolysis Targeting Chimera (PROTAC) Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share Forecast by Type (2021-2025)
Table 72. Global PROteolysis Targeting Chimera (PROTAC) Consumption Forecast by Application (2021-2025) (K Units)
Table 73. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global PROteolysis Targeting Chimera (PROTAC) Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share Forecast by Application (2021-2025)
Table 76. Arvinas Product Offered
Table 77. Arvinas PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 78. Arvinas Main Business
Table 79. Arvinas Latest Developments
Table 80. Arvinas Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Product Offered
Table 82. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 83. AstraZeneca Main Business
Table 84. AstraZeneca Latest Developments
Table 85. AstraZeneca Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 86. Kymera Product Offered
Table 87. Kymera PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 88. Kymera Main Business
Table 89. Kymera Latest Developments
Table 90. Kymera Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 91. Captor therapeutics Product Offered
Table 92. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 93. Captor therapeutics Main Business
Table 94. Captor therapeutics Latest Developments
Table 95. Captor therapeutics Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 96. Vividion Product Offered
Table 97. Vividion PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 98. Vividion Main Business
Table 99. Vividion Latest Developments
Table 100. Vividion Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 101. C4 therapeutics Product Offered
Table 102. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 103. C4 therapeutics Main Business
Table 104. C4 therapeutics Latest Developments
Table 105. C4 therapeutics Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 106. Merck Product Offered
Table 107. Merck Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 108. Merck Main Business
Table 109. Merck Latest Developments
Table 110. Merck PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 111. Cullgen Product Offered
Table 112. Cullgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 113. Cullgen Main Business
Table 114. Cullgen Latest Developments
Table 115. Cullgen Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 116. Genentech Product Offered
Table 117. Genentech PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 118. Genentech Main Business
Table 119. Genentech Latest Developments
Table 120. Genentech Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 121. Pfizer Product Offered
Table 122. Pfizer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 123. Pfizer Main Business
Table 124. Pfizer Latest Developments
Table 125. Pfizer Basic Information, Company Total Revenue (in $ million), PROteolysis Targeting Chimera (PROTAC) Manufacturing Base, Sales Area and Its Competitors
Table 126. Amgen Product Offered
Table 127. Amgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 128. Amgen Main Business
Table 129. Amgen Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 130. Amgen Latest Developments
Table 131. Bayer Product Offered
Table 132. Bayer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 133. Bayer Main Business
Table 134. Bayer Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 135. Bayer Latest Developments
List of Figures
Figure 1. Picture of PROteolysis Targeting Chimera (PROTAC)
Figure 2. PROteolysis Targeting Chimera (PROTAC) Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global PROteolysis Targeting Chimera (PROTAC) Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global PROteolysis Targeting Chimera (PROTAC) Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of ARV-110
Figure 7. Product Picture of ARV-471
Figure 8. Product Picture of KYM-001
Figure 9. Product Picture of Others
Figure 10. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type (2015-2020)
Figure 11. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Type (2015-2020)
Figure 12. PROteolysis Targeting Chimera (PROTAC) Consumed in Oncology
Figure 13. Global PROteolysis Targeting Chimera (PROTAC) Market: Oncology (2015-2020) (K Units)
Figure 14. Global PROteolysis Targeting Chimera (PROTAC) Market: Oncology (2015-2020) ($ Millions)
Figure 15. PROteolysis Targeting Chimera (PROTAC) Consumed in Others
Figure 16. Global PROteolysis Targeting Chimera (PROTAC) Market: Others (2015-2020) (K Units)
Figure 17. Global PROteolysis Targeting Chimera (PROTAC) Market: Others (2015-2020) ($ Millions)
Figure 18. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application (2015-2020)
Figure 19. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Application (2015-2020)
Figure 20. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Company in 2017
Figure 21. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Company in 2019
Figure 22. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Company in 2017
Figure 23. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Company in 2019
Figure 24. Global PROteolysis Targeting Chimera (PROTAC) Sale Price by Company in 2019
Figure 25. Global PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Regions 2015-2020
Figure 26. Global PROteolysis Targeting Chimera (PROTAC) Value Market Share by Regions 2015-2020
Figure 27. Americas PROteolysis Targeting Chimera (PROTAC) Consumption 2015-2020 (K Units)
Figure 28. Americas PROteolysis Targeting Chimera (PROTAC) Value 2015-2020 ($ Millions)
Figure 29. APAC PROteolysis Targeting Chimera (PROTAC) Consumption 2015-2020 (K Units)
Figure 30. APAC PROteolysis Targeting Chimera (PROTAC) Value 2015-2020 ($ Millions)
Figure 31. Europe PROteolysis Targeting Chimera (PROTAC) Consumption 2015-2020 (K Units)
Figure 32. Europe PROteolysis Targeting Chimera (PROTAC) Value 2015-2020 ($ Millions)
Figure 33. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption 2015-2020 (K Units)
Figure 34. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value 2015-2020 ($ Millions)
Figure 35. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries in 2019
Figure 36. Americas PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries in 2019
Figure 37. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type in 2019
Figure 38. Americas PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application in 2019
Figure 39. United States PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 40. United States PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 41. Canada PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 42. Canada PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 43. Mexico PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 44. Mexico PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 45. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries in 2019
Figure 46. APAC PROteolysis Targeting Chimera (PROTAC) Value Market Share by Regions in 2019
Figure 47. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type in 2019
Figure 48. APAC PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application in 2019
Figure 49. China PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 50. China PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 51. Japan PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 52. Japan PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 53. Korea PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 54. Korea PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 55. Southeast Asia PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 56. Southeast Asia PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 57. India PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 58. India PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 59. Australia PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 60. Australia PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 61. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries in 2019
Figure 62. Europe PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries in 2019
Figure 63. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type in 2019
Figure 64. Europe PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application in 2019
Figure 65. Germany PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 66. Germany PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 67. France PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 68. France PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 69. UK PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 70. UK PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 71. Italy PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 72. Italy PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 73. Russia PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 74. Russia PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 75. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Countries in 2019
Figure 76. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value Market Share by Countries in 2019
Figure 77. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Type in 2019
Figure 78. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption Market Share by Application in 2019
Figure 79. Egypt PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 80. Egypt PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 81. South Africa PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 82. South Africa PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 83. Israel PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 84. Israel PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 85. Turkey PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 86. Turkey PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 87. GCC Countries PROteolysis Targeting Chimera (PROTAC) Consumption Growth 2015-2020 (K Units)
Figure 88. GCC Countries PROteolysis Targeting Chimera (PROTAC) Value Growth 2015-2020 ($ Millions)
Figure 89. Global PROteolysis Targeting Chimera (PROTAC) Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 90. Global PROteolysis Targeting Chimera (PROTAC) Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 91. Americas PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 92. Americas PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 93. APAC PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 94. APAC PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 95. Europe PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 96. Europe PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 97. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 98. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 99. United States PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 100. United States PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 101. Canada PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 102. Canada PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 103. Mexico PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 104. Mexico PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 105. Brazil PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 106. Brazil PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 107. China PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 108. China PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 109. Japan PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 110. Japan PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 111. Korea PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 112. Korea PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 113. Southeast Asia PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 114. Southeast Asia PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 115. India PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 116. India PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 117. Australia PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 118. Australia PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 119. Germany PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 120. Germany PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 121. France PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 122. France PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 123. UK PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 124. UK PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 125. Italy PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 126. Italy PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 127. Russia PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 128. Russia PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 129. Spain PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 130. Spain PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 131. Egypt PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 132. Egypt PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 133. South Africa PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 134. South Africa PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 135. Israel PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 136. Israel PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 137. Turkey PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 138. Turkey PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 139. GCC Countries PROteolysis Targeting Chimera (PROTAC) Consumption 2021-2025 (K Units)
Figure 140. GCC Countries PROteolysis Targeting Chimera (PROTAC) Value 2021-2025 ($ Millions)
Figure 141. Arvinas PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 142. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 143. Kymera PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 144. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 145. Vividion PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 146. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 147. Merck PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 148. Cullgen PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 149. Genentech PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 150. Pfizer PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 151. Amgen PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Figure 152. Bayer PROteolysis Targeting Chimera (PROTAC) Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets